Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Feb;20(2):131-8.
doi: 10.1111/j.1525-1497.2005.30429.x.

Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians

Alexandra E Shields  1 , David Blumenthal, Kevin B Weiss, Catherine B Comstock, Douglas Currivan, Caryn Lerman
Affiliations

Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians

Alexandra E Shields et al. J Gen Intern Med. 2005 Feb.

Abstract

Objective: Smoking remains the leading cause of preventable death nationally. Emerging research may lead to improved smoking cessation treatment options, including tailoring treatment by genotype. Our objective was to assess primary care physicians' attitudes toward new genetic-based approaches to smoking treatment.

Design and setting: A 2002 national survey of primary care physicians. Respondents were randomly assigned a survey including 1 of 2 scenarios: a scenario in which a new test to tailor smoking treatment was described as a "genetic" test or one in which the new test was described as a "serum protein" test.

Participants: The study sample was randomly drawn from all U.S. primary care physicians in the American Medical Association Masterfile (e.g., those with a primary specialty of internal medicine, family practice, or general practice). Of 2,000 sampled physicians, 1,120 responded, yielding a response rate of 62.3%.

Measurements and main results: Controlling for physician and practice characteristics, describing a new test as "genetic" resulted in a regression-adjusted mean adoption score of 73.5, compared to a score of 82.5 for a nongenetic test, reflecting an 11% reduction in physicians' likelihood of offering such a test to their patients.

Conclusions: Merely describing a new test to tailor smoking treatment as "genetic" poses a significant barrier to physician adoption. Considering national estimates of those who smoke on a daily basis, this 11% reduction in adoption scores would translate into 3.9 million smokers who would not be offered a new genetic-based treatment for smoking. While emerging genetic research may lead to improved smoking treatment, the potential of novel interventions will likely go unrealized unless barriers to clinical integration are addressed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scenario.*Genetic/protein versions of this scenario were identical with the exception of scenario-specific language [in brackets].
See this image and copyright information in PMC

References

    1. Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2000. MMWR. 2002;51:642–5. - PubMed
    1. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2002;3:CD000146. - PubMed
    1. Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA. 1999;281:72–6. - PubMed
    1. Lerman C, Niaura R. Applying genetic approaches to the treatment of nicotine dependence. Oncogene. 2002;21:7412–20. - PubMed
    1. Heath AC, Martin NG. Genetic models for the natural history of smoking evidence for a genetic influence on smoking persistence. Addict Behav. 1993;18:19–34. - PubMed

Publication types